Evidence map›Paper›PMID 40159800›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

AI-Assisted Plasmonic Diagnostics Platform for Osteoarthritis and Rheumatoid Arthritis With Biomarker Quantification Using Mathematical Models.

Boyou Heo, Vo Thi Nhat Linh, Jun-Yeong Yang, Rowoon Park, Sung-Gyu Park, Min-Kyung Nam, Seung-Ah Yoo, Wan-Uk Kim, Min-Young Lee, Ho Sang Jung

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Boyou HeoAdvanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.
Vo Thi Nhat LinhAdvanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.
Jun-Yeong YangAdvanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.
Rowoon ParkAdvanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.
Sung-Gyu ParkAdvanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.
Min-Kyung NamDepartment of Biomedicine & Health Sciences, Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea.
Seung-Ah YooDepartment of Biomedicine & Health Sciences, Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea.
Wan-Uk KimCenter for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, 06591, Republic of Korea.
Min-Young LeeAdvanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.
Ho Sang JungAdvanced Bio and Healthcare Materials Research Division, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.ORCID 0000-0003-1776-1802

Funding

Korean government (MSIT) RS-2024-00399341Korean government (MSIT) RS-2024-00405574Korean government (MSIT) RS-2024-00432381Korean government (MSIT) RS-2024-00442793Ministry of Trade, Industry & EnergyNational Research Foundation
6 · The paper itself

Abstract

Osteoarthritis (OA) and rheumatoid arthritis (RA) are major causes of functional impairment, disability, and chronic pain, leading to a substantial rise in healthcare costs. Despite differences in pathophysiology, these diseases share overlapping features that complicate diagnosis, necessitating early, more accurate, and cost-effective diagnostic tools. This study introduces an innovative plasmonic diagnostics platform for rapid and accurate label-free diagnosis of OA and RA. The sensing platform utilizes a highly dense urchin-like gold nanoarchitecture (UGN), which enhances the surface plasmonic area to significantly amplify the Raman signal. The feasibility of the developed platform for arthritis diagnosis is demonstrated by analyzing the synovial fluid (SVF) of patients. Assisted by a machine learning model, Raman signals of OA and RA groups are successfully classified with high clinical sensitivity and specificity. Metabolic biomarkers are further investigated using mathematical models of combined Pearson correlation coefficient (PCC) and non-negative matrix factorization (NMF), suggesting valuable insights for arthritis biomarker quantification. In addition, RA severity is studied using the sensing platform by classifying results from the hematology test, achieving successful stage discrimination. This platform offers a versatile, affordable, and scalable in-clinic arthritis diagnostic solution with potential applications in diagnosing and monitoring other diseases through biofluid analysis.

Indexed as

Arthritis, RheumatoidBiomarkersModels, TheoreticalOsteoarthritisGoldHumansMachine LearningMetal NanoparticlesSpectrum Analysis, RamanSynovial FluidBiomarkersGoldmachine learningosteoarthritisrheumatoid arthritissurface‐enhanced Raman scatteringsynovial fluid

Identifiers

PMID40159800
PMCPMC12051836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.